Protocol Information

If you are interested in learning more about this study, please call or email the contact person below

Title A Phase 3, Multicenter, Randomized, Double-blind Study to Determine the Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects with Mild to Moderate Ulcerative Colitis, in both Acute and Maintenance Phases
Description Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis (PACE)

Study visits will be in downtown Buffalo, Amherst or Hamburg
Objective To assess clinical response to MMX mesalamine/mesalazine between a low and high dose in children and adolescents aged 5-17 years with mild to moderate Ulcerative Colitis (UC) or who are in remission.
Principal Investigator BAKER, SUSAN
Age Group Children
Drugs Involved
Clinical Trials.gov http://www.clinicaltrials.gov/ct2/show/NCT02093663/
Status Open
Key Eligibility Children ages 5-17
Mild to moderate ulcerative colitis
Disease Group Children's Health/Pediatrics; Crohn's Disease/Colitis; Digestive System
Treatment MMX Mesalamine/Mesalazine
Contact SONJA WILLIAMS
716-878-7198
sowilliams@upa.chob.edu